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Abstract
Background: There is limited information in the literature on the presentation and prognosis of
candidal urinary tract infection (UTI) in infants in the neonatal intensive care unit (NICU).
Methods: This was a prospective cohort study performed in 13 Canadian NICUs. Infants with
candidal UTI without extra-renal candidal infection at presentation were enrolled.
Results: Thirty infants fit the study criteria. Median birth weight and gestational age were 2595
grams (range 575-4255) and 35 weeks (range 24-41) with 10 infants being < 30 weeks gestation.
The most common primary underlying diagnosis was congenital heart disease (n = 10). The median
age at initial diagnosis was 16 days (range 6-84 days). Renal ultrasonography findings were
compatible with possible fungal disease in 15 of the 26 infants (58%) in whom it was performed.
Treatment was variable, but fluconazole and either amphotericin B deoxycholate or lipid-based
amphotericin B in combination or sequentially were used most frequently. Extra-renal candidiasis
subsequently developed in 4 infants. In 2 of these 4 infants, dissemination happened during
prolonged courses of anti-fungal therapy. Three of 9 deaths were considered to be related to
candidal infection. No recurrences of candiduria or episodes of invasive candidiasis following
treatment were documented.
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Conclusion: Candidal UTI in the NICU population occurs both in term infants with congenital
abnormalities and in preterm infants, and is associated with renal parenchymal disease and extra-
renal dissemination. A wide variation in clinical approach was documented in this multicenter study.
The overall mortality rate in these infants was significant (30%). In one third of the deaths, Candida
infection was deemed to be a contributing factor, suggesting the need for antifungal therapy with
repeat evaluation for dissemination in infants who are slow to respond to therapy.
Background
Isolation of Candida from the urine of newborns can be
indicative of contamination or of urinary tract infection.
Although bacteremia is a complication of less than 3% of
pediatric nosocomial bacterial urinary tract infections
(UTIs) [1], it is not clear how often candidal UTI is a pre-
cursor to candidemia or to candidal infection at other
sites. The primary purpose of this multi-center study was
to describe the presentation, therapy, and prognosis of
candidal UTIs in infants in the neonatal intensive care
unit (NICU) in the absence of documented extra-renal
infection at presentation.
Methods
This prospective study was performed in 13 tertiary level
NICUs in 9 cities in Canada by members of the Paediatric
Investigators Collaborative Network on Infections in Can-
ada (PICNIC). The study protocol was approved by the
institutional ethics review board at each center. As part of
a larger study [2], infants ≤ 90 days of age were prospec-
tively enrolled between February 1, 2001 and July 31,
2003 if they met one of three criteria: 1) Candida was iso-
lated from any sterile body site, 2) there was histologic or
ophthalmologic evidence of Candida infection, or 3) they
had candidal UTI, defined as growth of Candida  from
urine at > 106 CFU/L from a suprapubic aspirate or >
107CFU/L from a bladder catheter specimen (2). In this
report we describe those infants who fulfilled the third cri-
terion without documented evidence of extra-renal infec-
tion at the time of enrolment. Infants with Candida
isolated only from a bag urine were excluded. Institutions
were instructed to follow their usual protocols for the
diagnosis and treatment of candidal infection during the
study.
Demographic and clinical data were collected on a stand-
ard case report form and entered into an Access (Microsoft
Access 2002) database. Data were analyzed using SAS
(version 9.1, SAS Institute Inc, Cary, NC, USA.). The day
the first positive urine culture with significant growth of
Candida was submitted was considered to be the day of
identification of candiduria, recognizing that the onset of
candiduria may have been earlier in some cases. The local
investigator was asked to determine if Candida infection
contributed to death.
Results
Demographics and prior use of antifungal therapy
Thirty infants (16 males, 14 females, 23 singletons and 7
twins) met the study inclusion criteria (Table 1). The
median birth weight was 2595 grams (range 575 - 4255
grams) and the median gestational age (GA) was 35 weeks
(range 24 - 41 weeks). Ten infants (33%) were born prior
to 30 weeks. Delivery was vaginal (n = 13), via elective
cesarean section (n = 6) or via emergency cesarean section
(n = 11). The primary reason for NICU admission was
congenital heart disease (n = 10, of which 7 had a GA = 37
weeks), respiratory distress (n = 8), renal disease (n = 5),
sepsis (n = 3), gastrointestinal disease (n = 2), and trisomy
21 (n = 2). None of the infants received prophylactic top-
ical or systemic antifungal therapy. Thirteen infants
(43%) received systemic corticosteroids for 1 to 31 days
(median 3 days) prior to the candidal UTI. These con-
sisted of a wide range of doses of intravenous methylpred-
nisolone, hydrocortisone, or dexamethasone.
Extra-renal dissemination of candidal infection
Three of the 30 infants developed candidemia 2 to 41 days
following the candidal UTI and a fourth infant had evi-
dence of central nervous system candidal infection first
detected at autopsy (Table 2).
Clinical and laboratory features on the day of diagnosis of 
candidal UTI
Candidal UTI was diagnosed at a median of 16 days of age
(range 6 to 84 days). Three infants of GA 26, 30, and 41
weeks had possible congenital candidal infection with
diagnosis on days 6, 7, and 6 of life, respectively. The pla-
centa was examined for these 3 infants. The one from the
infant born at 41 weeks GA was normal while the 2 pre-
term infants showed chorioamnionitis and funisitis.
Clinical findings on the day of diagnosis included fever of
38.0°Celsius or higher (n = 7, 23%), feeding intolerance
(n = 2, 7%), and respiratory deterioration (n = 5, 17%).
Rash occurred on the day of diagnosis in all 3 infants with
possible congenital candidiasis (diaper dermatitis in the
preterm infants and a generalized excoriating rash in the
term infant). Three other infants born at 25, 27, and 35
weeks GA had diaper dermatitis when they presented on
days 48, 22, and 21 of lifeBMC Infectious Diseases 2009, 9:183 http://www.biomedcentral.com/1471-2334/9/183
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Table 1: Characteristics and outcome of 30 infants with candiduria from 13 Canadian neonatal intensive care units
Case GA BW Primary 
Diagnoses
Corticosteroids 
prior to candiduria
Day of life candiduria 
detected (Source)
Species Sites of extra-renal 
dissemination
Outcome
1 24 780 Trisomy 21, 
Prematurity
yes 19 (catheter) C. albicans None deceased
2 24 752 RDS, Prematurity yes 16 (catheter) C. glabrata None
3 33 2435 Renal Disease no 13 (catheter) C. albicans None
4 35 3320 Sepsis no 17 (catheter) C. parapsilosis None
5 41 3385 RDS, Renal 
Disease
yes 6 (catheter) C. albicans None
6 35 2570 Renal Disease no 15 (SPA) C. albicans None
7 38 3000 Omphalocele yes 11 (catheter) C. albicans None
8 26 635 CHD, Prematurity no 29 (catheter) C. parapsilosis None deceased
93 4 1 8 7 5 S e p s i s n o 1 5  ( S P A ) C. parapsilosis None
10 40 2800 CHD no 15 (catheter) C. lusitanae None
11 27 1025 RDS, Prematurity yes 22 (SPA) C. albicans None
12 40 3024 CHD yes 39 (catheter) C. parapsilosis None
13 37 3090 Renal Disease no 15 (catheter) C. albicans None
14 39 3400 CHD no 16 (catheter) C. tropicalis None deceased
15 38 4255 GI Disease no 14 (catheter) C. albicans None
16 35 2620 Renal Disease yes 21 (SPA) C. albicans None
17 40 3630 CHD yes 11 (catheter) C. albicans None
18 38 2750 Trisomy 21 yes 35 (catheter) C. albicans None deceased
19 40 3500 CHD yes 15 (catheter) C. tropicalis None deceased*
20 39 3930 CHD no 84 (catheter) C. albicans None deceased
21 40 3030 Renal Disease no 11 (SPA) C. albicans None
22 30 1445 Sepsis no 7 (catheter) C. albicans None
23 25 815 RDS, Prematurity yes 48 (catheter) C. lusitanae None
24 24 650 RDS, Prematurity no 9 (SPA) C. albicans None
25 25 725 RDS, Prematurity no 35 (catheter) C. albicans None
26 24 575 RDS, Prematurity yes 56 (catheter) C. albicans NoneBMC Infectious Diseases 2009, 9:183 http://www.biomedcentral.com/1471-2334/9/183
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Positive urine cultures were obtained via suprapubic aspi-
rate (n = 8) or bladder catheter (n = 22). Seventy percent
were C. albicans (Table 3). Urinalysis was obtained within
24 hours of diagnosis of candidal UTI for only 10 infants.
Two infants had no pyuria, 2 had an occasional WBC/
HPF, 2 had 1-10 WBCs/HPF, and 4 had >10 WBCs/HPF.
Hematologic abnormalities included a peripheral leuko-
cyte count of <5 × 109/L in 1 infant and >25 × 109/L in 2
infants, an absolute granulocyte count of >10 × 109/L in
10 infants, and platelets <100 × 109/L in 6 infants. Serum
creatinine at diagnosis was <60 μmol/L in 16 infants, 61-
100 μmol/L in 5 infants, 101-150 μmol/L in 3 infants,
>150 μmol/L in 4 infants and not recorded in 2 infants.
Blood culture was performed and was negative for fungi in
24 of the 30 infants on the day of diagnosis of candidal
UTI and in another 2 infants prior to initiation of antifun-
gals. Of the four infants who did not have blood cultures
prior to antifungals, three subsequently had no clinical or
laboratory evidence of invasive candidal infection but one
27 26 830 Prematurity, NEC no 6 (SPA) C. albicans Blood
28 28 1170 CHD no 58 (catheter) C. albicans Brain deceased*
29 33 2200 CHD no 77 (SPA) C. parapsilosis Blood deceased
30 37 3225 CHD yes 50 (catheter) C. albicans Blood deceased*
BW - birthweight; CHD - congenital heart disease; GA - gestational age; NEC - necrotizing enterocolitis; RDS - respiratory distress syndrome; SPA 
- suprapubic aspirate
* Death was thought to be related to candidal infection
Table 1: Characteristics and outcome of 30 infants with candiduria from 13 Canadian neonatal intensive care units (Continued)
Table 2: Infants who developed extra-renal dissemination of candidal infection from a cohort of 30 infants diagnosed with candiduria
Patient 
number
GA Primary 
diagnosis
Extra-
renal 
site
Species Days 
between 
positive 
urine culture 
and positive 
culture at 
extra-renal 
site
Cultures 
performed 
between date 
of positive 
urine and date 
of positive 
culture at 
extra-renal 
site1
Therapy 
between 
candiduria 
and positive 
culture at 
extra-renal 
site
Outcome 
of 
candidal 
infection
Treatment 
after 
diagnosis of 
extra-renal 
candidal 
infection
1 26 weeks Prematurity Blood C. albicans 2 1 urine culture 
positive for C. 
albicans
None Survived 32 days AMP, 
FCZ and 5FC 
in various 
combinations
2 28 weeks Congenital 
heart 
disease
CNS (at 
autopsy)2
C. albicans 11 4 negative blood 
cultures
7 days AMP Died None
3 33 weeks Congenital 
heart 
disease
Blood C. 
parapsilosis
41 5 negative urine 
cultures3
13 days AMP Survived4 28 days AMP 
and L-AMP
4 37 weeks Congenital 
heart 
disease
Blood C. albicans 32 5 urine cultures 
positive for C. 
albicans and 4 
negative blood 
cultures
26 days AMP, 
FCZ or both5
Died 4 days L-AMP 
and FCZ
AMP - amphotericin B deoxycholate; CNS - central nervous system; FCZ - fluconazole; GA - gestational age; L-AMP- lipid-based amphotericin B; 
5FC - 5 flucytosine
1All had a negative blood culture on the day of diagnosis of candiduria
2Prior to the positive urine culture, had 7 negative blood cultures and 2 negative CSF cultures. Between the onset of candiduria and death had 4 
negative blood cultures but cerebrospinal fluid not obtained
3 Blood culture was not performed initially or until 41 days after the date of the positive urine culture
4Ultimately died of congenital heart disease
5There was a 5-day gap after the first 5 days of therapy.BMC Infectious Diseases 2009, 9:183 http://www.biomedcentral.com/1471-2334/9/183
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had a positive blood culture 41 days later (Table 1). Lum-
bar puncture was performed in only 5 infants within 2
days of the diagnosis of candidal UTI. A cell count was
available in 3 of these infants, of whom 2 had pleocytosis
(WBC 44 × 106/L (100% monocytes) with RBC 62 × 106/
L, and WBC 315 × 106/L (45% polymorphonuclear cells)
with RBC 12,720 × 106/L) and all 5 CSF cultures were ster-
ile. Four other infants had CSF obtained more than 2 days
after the diagnosis of UTI but prior to laboratory docu-
mentation of clearance of candiduria. All CSF cultures
were sterile, and there was no pleocytosis in the 2 cases
where a cell count was available.
Radiographic findings
Renal ultrasonography revealed abnormalities compati-
ble with fungal disease in 15 of the 26 infants (58%) in
whom it was performed. Twenty-four of the 26 scans were
performed within 4 days of the onset of candiduria. These
abnormalities included diffuse parenchymal echogenicity
(n = 5), focal parenchymal echogenicity (n = 1), unspeci-
fied echogenicity (n = 1), dilatation of the collecting ducts
(n = 3) and both parenchymal echogenicity and dilatation
of the collecting ducts (n = 5). Almost all abnormalities
were bilateral. The radiologic appearance was consistent
with "fungal balls" in 3 of these 15 infants - a term infant
with diffuse parenchymal disease and 2 infants born at 25
and 35 weeks GA with dilated collecting ducts, none of
whom developed candidemia. Follow-up imaging was
not performed in these 3 infants.
Ultrasonography of the liver and spleen was abnormal in
6 of the 16 infants (37.5%) in whom it was performed,
revealing hepatomegaly (n = 2), a solitary hepatic heman-
gioma, a calcified hepatic thrombosis, a splenic
hematoma, and diffusely abnormal splenic echogenicity
of uncertain significance. None of the findings were con-
sidered to be suggestive of hepatosplenic candidiasis.
Ophthalmologic findings
None of the 12 infants who had fundoscopic examina-
tions had evidence of fungal retinitis.
Therapy
Two infants did not receive antifungal therapy - a term
infant with renal failure who was treated for a Pseu-
domonas UTI and had no follow-up urine cultures prior to
discharge (patient 13 in Table 1) and an infant with tri-
somy 21 who had candidal UTI 3 days prior to death with
no evidence of Candida infection at autopsy (patient 18 in
Table 1). Therapy for the remaining infants consisted of
fluconazole (FCZ), amphotericin B deoxycholate (AMP),
lipid-based amphotericin B (L-AMP) and 5-fluctyosine (5-
FC) in various combinations (Figure 1). For the 22 infants
who survived to the end of therapy and did not develop
extra-renal candidal infection, 4 infants received AMP or
L-AMP alone, 6 infants received FCZ alone, 10 infants
received a combination of AMP or L-AMP and FCZ and 2
infants received AMP or L-AMP with FCZ and 5-FC. The
median total duration of antifungals in these 22 infants
was 16.5 days (range 5-75 days). For the 3 infants with
suspected renal fungal balls, one of the term infants
received just two days of L-AMP prior to death (Table 1)
while the 2 survivors were treated for 14 and 75 days with
sequential AMP and FCZ.
Complications of Therapy
A clinically significant rise in creatinine (defined as an
increase of ≥ 20% to a level ≥60 μmol/l) was documented
in 5 infants while on therapy (a rise from 142 to 178
μmol/L on day 3 of AMP, a rise from 171 to 310 μmol/L
on day 9 of L-AMP following a 3 day course of AMP, a rise
from 104 to 137 and from 36 to 87 μmol/L on days 2 and
5 of L-AMP respectively and a rise from 32 to 98 μmol/L
on day 5 of FCZ). For the 3 infants with suspected fungal
balls, the highest serum creatinine levels were 66, 91, and
Table 3: Species of Candida in 30 infants in neonatal intensive care units with candiduria
Species Number of cases of candiduria (%) - 
current study; 
n = 301
Number of cases of candiduria 
(%) (3) 
n = 25
Number of cases of candiduria 
(%) (4) 
n = 362
Years of study 2001-2003 1989-1995 1982-1993
Candida albicans 21 (70%) 15 (60%) 26 (72%)
Candida parapsilosis 4 (13%) 8 (32%) 7 (19%)
Candida tropicalis 2 (7%) 2 (8%) 1 (3%)
Candida lusitaniae 2 (7%) 0 0
Candida glabrata 1 (3%) 0 2 (6%)
1Two of the infants with C. albicans and one with C. parapsilosis were fungemic.
2 Study reports 41 infants but microbiologic data only provided for 36 infantsBMC Infectious Diseases 2009, 9:183 http://www.biomedcentral.com/1471-2334/9/183
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97 μmol/L respectively. Hypokalemia (defined as serum
potassium < 3.3 mEq/L) was documented in 10 infants
(33%) of whom 4 were born prior to 30 weeks GA. Attrib-
uting hypokalemia to specific antifungals was not possi-
ble as 9 of these infants were treated with sequential or
combination drugs. New-onset thrombocytopenia (plate-
lets <100 × 109/L) was documented after commencing
antifungals in 5 infants (17%). Four infants developed
hypotension while on antifungal therapy (two on FCZ
and one on each of AMP and L-AMP).
Outcome
There were 9 deaths among the 30 infants in the study
(30%), all in infants with significant underlying condi-
tions (7 with congenital heart disease and 2 with trisomy
21). In three of these deaths, Candida  infection was
thought to be a contributing factor. Two of the deaths
were in infants who developed disseminated disease
(patients 2 and 4 in Table 1), and one occurred in an
infant without evidence of extra-renal candidal infection.
The latter infant was born at 40 weeks GA with congenital
heart disease and died following 2 days of therapy for can-
didal UTI, with suspected renal fungal balls on renal ultra-
sonography. No autopsy was performed. Five of the 6
other infants who died had autopsies, none of which
revealed evidence of candidal infection. No recurrences of
candiduria or isolation of Candida from a sterile site were
documented prior to hospital discharge among the 21 sur-
vivors, but 5 infants did not have follow-up urine cultures
obtained.
Discussion
Multiple previous studies outline the epidemiology and
clinical course of invasive candidiasis in the NICU, but
there have been limited studies of candidal UTI in the
absence of extra-renal disease as detected by routine inves-
Antifungal therapy offered to 30 infants with candiduria in neonatal intensive care units Figure 1
Antifungal therapy offered to 30 infants with candiduria in neonatal intensive care units. AMP - amphotericin B 
deoxycholate; d-days; FCZ - fluconazole; L-AMP- lipid-based amphotericin B; 5FC - 5 flucytosine.
                      30 infants with candiduria 
26 without extra-renal candidal infection       4 developed extra-renal infection
1
1 survived with  1 died with 2 died on      22 survived to completion 
no antifungals   no antifungals    antifungals
2               of antifungals
AMP      LA        AMP/LA   FCZ        AMP & FCZ
3   LA & FCZ
4 AMP,LA,FCZ
3     LA,FCZ,5FC
3 AMP,FCZ,5FC
3
13-17d   14 d       14d             10-21d    5-75d               8-21d           49                      61d 59 d 
N=2       N=1       N=1            N=6       N=7                 N=2             N=1                     N=1                N=1
1 See Table 1 for details of their therapy and outcome. 
2 Death occurred on day 2 of L-AMP and day 5 of FCZ 
3 Given sequentially or in combination 
Given sequentially 
4BMC Infectious Diseases 2009, 9:183 http://www.biomedcentral.com/1471-2334/9/183
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tigations. This report describes 30 such cases presenting to
13 Canadian NICUs over a 30-month period, many in
term or near-term infants with major congenital abnor-
malities of the heart or kidneys. In addition our results
suggest a lack of distinguishing clinical or laboratory fea-
tures at diagnosis, a high rate of abnormalities on renal
ultrasonography (>50%), and a significant proportion
(one third) of the total mortality related to Candida infec-
tion.
Our finding of candidal UTI in term infants with congen-
ital anomalies differs from two previously published stud-
ies of candidal UTIs in NICUs. Philips et al used an
identical definition for candidal UTI to the current study
but only enrolled infants 7 days of age or older (n = 25)
[3]. The second study by Bryant et al enrolled infants from
birth (n = 41) but accepted any growth of Candida from a
catheterized urine as being indicative of a UTI [4]. These
previous studies described candidal UTIs mainly in very
low birth weight infants (median gestational age 26 weeks
[3] and 27 weeks [4] versus 35 weeks in the current study).
This discrepancy is likely due to our exclusion of infants
who had candidemia on the day of diagnosis of candidal
UTI. In the cohort of 66 infants with systemic candidiasis
that were part of our larger study who met the first inclu-
sion criteria but are not included in the current report, 8
infants had both blood and urine cultures positive for
Candida and their median gestational age was 25.5 weeks
(unpublished data), consistent with these previously pub-
lished studies. Differences in NICU populations between
the studies may also be a factor with the current multi-
center study including a higher proportion of term infants
with congenital heart disease than many studies of single
NICUs. Although there are no previous studies looking at
candidal UTI in term or near-term infants in NICU, a
study that looked at invasive candidiasis in infants with a
birth weight over 2500 grams described 13 of 17 infants
(76%) with serious congenital anomalies [5]. This pattern
fits with the current study where two-thirds of the infants
were born after 29 weeks gestation and over half had seri-
ous congenital anomalies. In a study from the United
Kingdom of infants with fungal infections and a birth-
weight < 1500 grams, 26 of 94 cases had funguria with 6
having isolated funguria [6]. The species of Candida were
comparable in all NICU candidal UTI studies to date
(Table 2).
On renal ultrasonography, parenchymal changes predom-
inated in the current study, suggesting the possibility of
unrecognized hematogenous spread of Candida in infants
who are suspected to have candidal infection limited to
the urinary tract. Ascending infection would be expected
to result in isolated pelvicalyceal disease, with only 3 of
the 15 abnormal renal ultrasounds fitting this pattern.
However, the terminology for renal ultrasonography
reporting in neonates is not uniform. Renal fungal balls or
abscesses were suspected in 35% [3] and 42% [4] of the 55
infants with renal imaging or autopsy diagnoses in the
previous studies. In the current study, only 12% of the 26
infants with renal imaging had a fungal ball mentioned in
the report, but many had changes that appeared to be con-
sistent with those reported as fungal balls in a previous
study [4]. Renal fungal balls can be confused with fibrin,
blood clots, necrotic papillae, nephrocalcinosis, or
tumors on renal ultrasonography [7] so that the interpre-
tation may be influenced by the information provided to
the radiologist about the possibility of candidal infection.
In one study, about half of the suspected fungal balls were
apparent only on follow-up ultrasounds [4] which were
not routinely performed in the current study.
Although surgical intervention for renal fungal disease in
the collecting system has been described in numerous case
reports [7], it was not required for infants with fungal
balls in our study. For the 66 infants with candidal UTI
described in the two previous case series [3,4]22 infants
had suspected fungal balls with 2 having partial obstruc-
tion but surgery was required for only one infant with a
renal abscess [4]. In another recent study of 9 infants with
suspected renal fungal balls, surgical management was
not required [8]. This suggests that medical management
can be anticipated to be successful in the majority of cases,
even in the presence of documented fungal balls on imag-
ing, unless there is concomitant total obstruction.
The need for, choice and duration of antifungal treatment
for candidal UTI in the absence of extra-renal disease has
not been studied and there are no widely-accepted guide-
lines, explaining the marked variation in therapy in the
current study. Two of the 3 deaths that were thought to be
related to candidal infection were a result of dissemina-
tion of disease, indicating that cases with "apparent iso-
lated candiduria" may later disseminate or may have
undetected foci of infection at non-renal distant sites. The
significant rate of extra-renal dissemination (13.3%) sup-
ports the use of systemic antifungal therapy when candi-
duria occurs with a significant colony count in the NICU.
Most infants with candidal UTI in previous reports were
successfully treated with AMP or FCZ, typically given for a
minimum of 7 days after urine cultures became sterile [7].
Much longer courses have often been given if changes are
noted on renal ultrasonography, but it appears that there
is no need to document resolution of these changes prior
to stopping therapy [7] There were only 2 cases of sus-
pected treatment failure in the current study where death
was attributable to candidal infection despite 7 or more
days of appropriate therapy, both in infants with extra-
renal dissemination (Table 1). There were no recurrences
of candiduria, suggesting that any of the multiple regimesBMC Infectious Diseases 2009, 9:183 http://www.biomedcentral.com/1471-2334/9/183
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used by clinicians for candidal UTI are likely to be success-
ful if extra-renal invasive candidal infection has been
excluded. Two of the three cases of candidemia occurred
after long courses of antifungals, suggesting that extra-
renal candidal infection should be sought even in infants
on treatment with a slow response to therapy. The role of
parenteral prophylactic antifungals for candiduria could
not be addressed in the current study as they were not
used in any of the NICUs.
The primary limitation in drawing conclusion from this
study is that although the patients were enrolled prospec-
tively, investigations for dissemination were at the discre-
tion of the attending physician. This resulted in not all
patients being consistently evaluated for meningitis, retin-
itis, renal parenchymal disease, recurrent candiduria, or
even candidemia. However, we recognize that false-nega-
tive blood and CSF cultures occur frequently in neonatal
candidasis so associated morbidity is not always recog-
nized even when infants are fully evaluated for dissemi-
nated disease. Nonetheless, even though it is widely
accepted that all infants with candidemia should be inves-
tigated for end-organ damage [7], the need for full inves-
tigation of infants with candiduria in the absence of
candidemia is less clear from the previous literature. The
role of fundoscopy in infants with candiduria alone is not
clear although a study has shown a higher incidence of
candidial retinitis with candidaemia of greater gestational
age [9], suggesting that fundoscopy is indicated even in
term infants with extra-renal candidiasis.
Further limitations are that it would have been ideal to
have all renal ultrasounds interpreted by a single radiolo-
gist, and that changes in management of infants will have
occurred since this study was performed. For example,
fewer infants would be exposed to post-natal corticoster-
oids and echindocandins are now used as antifungal ther-
apy in some centers.
One of the limitations of all studies to date is that defini-
tions devised for the diagnosis of bacterial UTIs have been
extrapolated to fungal UTIs, without validation of these
definitions in any age group [1]. There are no standard
definitions for colony counts defining UTIs in children
with indwelling bladder catheters [1] which would
include a small number of infants in the current study.
The fact that over half of the renal ultrasounds in our
study demonstrated abnormalities consistent with fungal
infection of the renal parenchyma or collecting system
suggests that the specificity of the definitions used is rea-
sonable. It is however possible that clinically significant
fungal UTIs can occur at lower colony counts than those
applied in this study, as has been described in infants with
suspected fungal balls [10]. In addition, infants with fun-
gal UTI may have been missed if only a bag urine had
been submitted or if antifungals had been started prior to
obtaining the urine specimen.
Conclusion
In this study of Canadian neonates, we were able to show
that neonates presenting as candidal UTI without dissem-
ination, within the NICU population of low birth weight
infants and older gestational age infants with underlying
illness, is associated with significant morbidity and mor-
tality. It is difficult to separate out the effect of candiduria
on outcome versus the tendency of infants with a poor
prognosis to develop candiduria. There is significant vari-
ation in the diagnosis and management of candiduria in
academic tertiary level NICUs in Canada. The cases of
extra-renal invasive candidal disease suggest that investi-
gation for Candida in the blood, cerebrospinal fluid, renal
parenchyma and retina may be indicated along with sys-
temic antifungal therapy. Evidence of extra-renal spread in
the face of appropriate systemic therapy may be a poor
prognostic sign, and is not restricted to extremely prema-
ture infants. Multi-center randomized trials are needed to
determine the optimal therapy and duration of treatment
for this relatively rare entity.
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